The sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control assessed by continuous glucose monitoring even on a low-carbohydrate diet.

The sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control assessed by continuous glucose monitoring even on a low-carbohydrate diet. Diabetes Obes Metab. 2015 Dec 6; Authors: Nishimura R, Omiya H, Sugio K, Ubukata M, Sakai S, Samukawa Y Abstract This randomized, double-blind, placebo-controlled, crossover study was the first to determine the effects of luseogliflozin in combination with a low-carbohydrate diet (LCD) on 24-h glucose variability assessed by continuous glucose monitoring (CGM). Eighteen Japanese patients with type 2 diabetes were randomized into two groups in which patients first received luseogliflozin 2.5 mg once-daily then placebo for 8 days each, or vice versa. Patients took luseogliflozin or placebo with a normal-carbohydrate diet (NCD) on Day 7 and with the LCD on Day 8. CGM was performed on both days. Luseogliflozin significantly reduced glucose exposure in terms of the area under the curve over 24 h when administered with the NCD (difference vs. placebo: -555.6 mg/dL·h [1 mg/dL = 0.0556 mmol/L], p < 0.001) or with the LCD (-660.7 mg/dL·h, p < 0.001). No hypoglycaemia was observed over 24 h with either diet. Although glucose levels were lower with the LCD than the NCD in the placebo treatment period, luseogliflozin with the LCD improved glycaemic control throughout the day to nearly the same extent as luseogliflozin with the NCD, without inducing hypoglycaemia. PMID: 2...
Source: Diabetes Metab - Category: Endocrinology Authors: Tags: Diabetes Obes Metab Source Type: research